Glenmark Recalls 114 Batches of Potassium Chloride.

CONTROLLED release preparations; PRODUCT recall; HYPERKALEMIA; SOLUBILITY; PHARMACEUTICAL industry; ARRHYTHMIA; POTASSIUM chloride; DISEASE risk factors

The article discusses Glenmark Pharmaceuticals' recall of 114 batches of Potassium Chloride Extended-Release Capsules due to failed dissolution, potentially causing high potassium levels, or hyperkalemia. Topics discussed include the risks associated with undissolved potassium chloride, such as hypertension, heart failure, or renal dysfunction; the lack of reported adverse events so far; and details about the affected batches' expiration dates and identification numbers.